A multicenter, randomized controlled trial evaluating a theory driven, behavior change intervention centered on mobile health and task sharing to improve self-care and outcomes in patients with chronic heart failure. PANACEA- HF trial (Part of the PANACEA -HF project)

St Johns Research Institute0 sites301 target enrollmentTBD

Overview

Phase: 未知
Intervention: Not specified
Conditions: Health Condition 1: I504- Combined systolic (congestive) anddiastolic (congestive) heart failureHealth Condition 2: I509- Heart failure, unspecified
Sponsor: St Johns Research Institute
Enrollment: 301
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

TBD

End Date

September 1, 2021

Last Updated

2 years ago

Study Type

Interventional

Sponsor

St Johns Research Institute

•In\-patients,1,Patients with a clinical diagnosis of heart failure on a high ceiling diuretic,2,In NYHA class I, II or III after stabilization and shifted to the general ward, commenced on a Renin Angiotensin Aldosterone (RAAS) blocker and or a beta blocker or vasodilator,3 If in NYHA IV, daily dose of Furosemide or high ceiling diuretic equivalent 100 mg day at discharge
•Out\-patients, 1, Patients with a prior clinical diagnosis of chronic heart failure, 2, In NYHA class I, II or III with a history of at least 1 re\-hospitalization in the last 12 months, 3, Currently on a RAAS blocker and or beta blocker vasodilator, 4, Either a history of or currently on a high ceiling diuretic

•In\-patients, 1, Patients in acute heart failure with a reversible cause for heart failure as judged by the treating cardiologist or internist, 2, Acute Kidney Injury due to heart failure which precludes the use of Renin,Angiotensin,Aldosterone blockers until discharge maybe considered for inclusion during OPD follow\-up if RAAS blockers commenced, 3, Diagnosed with end stage renal disease or requiring renal replacement therapy, 4, Hemodynamic instability or shock requiring vasopressors in the current admission, 5, Patients with clinically diagnosed severe mental illness such as severe depression Or patients with moderate depression and no caregivers, 6, Patients having significant cognitive dysfunction during screening and have no caregiver, 7, Patients who in the opinion of the treating physician has a poor prognosis with foreseen survival less than 12 months
•Out\-patients, 1, Renal function status precludes the use of RAAS blockers, 2, End stage renal disease requiring any form of renal replacement therapy, 3, Patients having significant cognitive dysfunction during screening and have no caregiver, 4, Patients who in the opinion of the treating physician has a poor prognosis with foreseen survival less than 12 months.